Microbot Medical (NASDAQ:MBOT – Get Free Report) and Nexalin Technology (NASDAQ:NXL – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.
Earnings & Valuation
This table compares Microbot Medical and Nexalin Technology”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Microbot Medical | $346,000.00 | 183.64 | -$13.14 million | ($0.24) | -3.94 |
| Nexalin Technology | $217,155.00 | 7.13 | -$8.22 million | ($14.41) | -0.15 |
Institutional & Insider Ownership
16.3% of Microbot Medical shares are held by institutional investors. Comparatively, 0.6% of Nexalin Technology shares are held by institutional investors. 4.7% of Microbot Medical shares are held by insiders. Comparatively, 16.9% of Nexalin Technology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Microbot Medical and Nexalin Technology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Microbot Medical | N/A | -21.87% | -20.76% |
| Nexalin Technology | -4,141.94% | -278.24% | -218.42% |
Analyst Ratings
This is a breakdown of recent ratings for Microbot Medical and Nexalin Technology, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Microbot Medical | 1 | 1 | 3 | 0 | 2.40 |
| Nexalin Technology | 1 | 1 | 0 | 0 | 1.50 |
Microbot Medical presently has a consensus target price of $6.38, indicating a potential upside of 573.89%. Given Microbot Medical’s stronger consensus rating and higher probable upside, research analysts clearly believe Microbot Medical is more favorable than Nexalin Technology.
Volatility and Risk
Microbot Medical has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Nexalin Technology has a beta of 4.08, meaning that its stock price is 308% more volatile than the S&P 500.
Summary
Microbot Medical beats Nexalin Technology on 10 of the 14 factors compared between the two stocks.
About Microbot Medical
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
About Nexalin Technology
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.
